6,7-dimethoxyquinoline-3-carbonitrile | 209521-75-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6,7-dimethoxyquinoline-3-carbonitrile
• 英文别名: 6,7-dimethoxy-3-quinolinecarbonitrile；6,7-Dimethoxy-quinoline-3-carbonitrile
• CAS: 209521-75-5
• 化学式: C₁₂H₁₀N₂O₂
• 分子量: 214.224
• InChiKey: BPOVRKHDPWHCSU-UHFFFAOYSA-N

物化性质

• 沸点：
  381.7±37.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  55.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6,7-dimethoxyquinoline-3-carbonitrile 在 间氯过氧苯甲酸 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 生成 2-氯-6,7-二甲氧基-3-喹啉甲腈
  参考文献：
  名称：

  喹啉系列中带有刚性酰胺部分的稳定的退火手性NADH模型：在Merrifield树脂上的合成，反应性和接枝

  摘要：

  描述了衍生自喹啉的新的手性烟酰胺腺嘌呤二核苷酸氢化模型的合成。使用仿生方法，通过将手性助剂包括在内酰胺结构中，获得酰胺羰基的面外定位。结果表明，喹啉结构的苯环上的给电子基团是在苯甲酸甲酰甲酯还原过程中获得高化学收率所必需的。已经观察到对映选择性作为镁离子浓度的函数的有趣变化。在最佳条件下，获得高达95％ee（R）的扁桃酸甲酯。为了促进这些模型的回收，已经开发了在Merrifield树脂上接枝试剂4的方法。所得聚合物负载的试剂在不对称还原苯甲酰基甲酸甲酯中测试了图4。

  DOI：

  10.1016/s0040-4020(01)00166-1
• 作为产物：
  描述：

  (E)-3-(3,4-Dimethoxy-phenylamino)-2-formyl-acrylonitrile 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 生成 6,7-dimethoxyquinoline-3-carbonitrile
  参考文献：
  名称：

  An efficient synthesis of 3-cyanoquinoline derivatives

  摘要：

  A short aid efficient method is reported for the preparation of 3-cyanoquinoline derivatives. Reaction of 3,3-dimethoxy-2-formyl-propanenitrile sodium salt 1 with various anilines 2 afforded (E) enamines 3 which were subsequently isomerized into (Z) enamines 4 and cyclized in a one pot procedure to give 3-cyanoquinolines 5 in good yields. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)00677-7

文献信息

• Synthesis, radiosynthesis and biological evaluation of 1,4-dihydroquinoline derivatives as new carriers for specific brain delivery
  作者：Lénaïg Foucout、Fabienne Gourand、Martine Dhilly、Pierre Bohn、Georges Dupas、Jean Costentin、Ahmed Abbas、Francis Marsais、Louisa Barré、Vincent Levacher

  DOI：10.1039/b909650g

  日期：——

  In spite of numerous reports dealing with the use of 1,4-dihydropyridines as carriers to deliver biological active compounds to the brain, this chemical delivery system (CDS) suffers from poor stability of the 1,4-dihydropyridine derivatives towards oxidation and hydration reactions seriously limiting further investigations in vivo. In an attempt to overcome these limitations, we report herein the first biological evaluation of more stable annellated NADH models in the quinoline series as relevant neuroactive drug-carrier candidates. The radiolabeled 1,4-dihydroquinoline [11C]1a was prepared to be subsequently peripherally injected in rats. The injected animals were sacrificed and brains were collected. The radioactivity measured in rat brain indicated a rapid penetration of the carrier [11C]1a into the CNS. HPLC analysis of brain homogenates showed that oxidation of [11C]1a into the corresponding quinolinium salt [11C]4a was completed in less than 5 min. An in vivo evaluation in mice is also reported to illustrate the potential of such 1,4-dihydroquinoline derivatives to transport a neuroactive drug in the CNS. For this purpose, γ-aminobutyric acid (GABA), well known to poorly cross the brain blood barrier (BBB) was connected to this 1,4-dihydroquinoline-type carrier. After i.p. injection of 1,4-dihydroquinoline-GABA derivative 1b in mice, a significant alteration of locomotor activity (LMA) was observed presumably resulting from an enhancement of central GABAergic activity. These encouraging results give strong evidence for the capacity of carrier-GABA derivative 1b to cross the BBB and exert a pharmacological effect on the CNS. This study paves the way for further progress in designing new redox chemical delivery systems.

  尽管有许多关于使用1,4-二氢吡啶作为载体将生物活性化合物递送至大脑的报道，但这种化学递送系统（CDS）受到1,4-二氢吡啶衍生物对氧化和水合反应稳定性差的严重限制，从而限制了体内进一步研究。为了克服这些限制，我们在此首次报道了更稳定的环联式NADH模型在喹啉系列中的生物学评估，这些模型作为相关的神经活性药物载体候选物。制备了放射性标记的1,4-二氢喹啉[11C]1a以随后在 rats 中进行外周注射。注射的动物被牺牲并收集大脑。在 rat 大脑中测得的放射活性表明载体[11C]1a快速渗透至中枢神经系统（CNS）。对脑组织匀浆的高效液相色谱（HPLC）分析显示，[11C]1a氧化为相应的喹啉盐[11C]4a的过程在不到5分钟内完成。还报道了在 mice 中的体内评估，以说明这类1,4-二氢喹啉衍生物在CNS中运输神经活性药物的潜力。为此目的，将 γ-氨基丁酸（GABA）——因其难以穿越血脑屏障（BBB）而闻名——连接到这种1,4-二氢喹啉型载体上。在 mice 中腹腔注射1,4-二氢喹啉-GABA衍生物1b后，观察到运动活动（LMA）的显著改变，这可能是由于中枢GABA能活性的增强所致。这些令人鼓舞的结果为1b载体-GABA衍生物穿越BBB并在CNS中发挥药理作用的能力提供了有力证据。这项研究为设计新的氧化还原化学递送系统开辟了道路。
• New Efficient Conditions for the Reduction with NADH Models
  作者：J. L. Vasse、P. Charpentier、V. Levacher、G. Dupas、G. Quéguiner、J. Bourguignon

  DOI：10.1055/s-1998-1876

  日期：1998.10

  New conditions were used for the efficient reduction of various nitroalkenes and two prochiral ketones by using NADH mimics. The present procedure is very useful since it does not involve magnesium perchlorate which is replaced by magnesium bromide in THF. High conversions were observed. The new conditions were checked in asymmetric reductions.

  采用新的条件，通过使用NADH类物质有效还原了多种亚硝基烯烃和两个前手性酮。这一方法非常实用，因为它不涉及过氯酸镁，而是用溴化镁替代，溶剂为四氢呋喃。观察到了高转化率。新条件在不对称还原中得到了验证。
• Ru(III)-catalyzed construction of variously substituted quinolines from 2-aminoaromatic aldehydes (ketones) and isoxazoles: Isoxazoles as cyclization reagent and cyano sources
  作者：Di Hu、Chao Pi、Wei Hu、Xiliang Han、Yangjie Wu、Xiuling Cui

  DOI：10.1016/j.cclet.2021.12.072

  日期：2022.8

  N-O bond cleavage and fragmentation. Variously substituted (especially 6- or 7-substituted) quinolines could be easily afforded. This procedure features wide functional group compatibility, efficiency and avoiding toxic cyano source. Meanwhile, this protocol could be successfully applied to scale-up synthesis. Further chemical transformations of 3-cyanoquinoline could give some valuable skeletons, demonstrating

  开发了 Ru(Ⅲ) 催化的 2-氨基芳香醛（酮）和异恶唑的环化反应，得到多种 3-氰基喹啉。值得注意的是，异恶唑通过NO 键断裂和断裂充当环化试剂和无毒氰基源。可以很容易地提供各种取代（尤其是 6 或 7 取代）的喹啉。该程序具有广泛的官能团兼容性、效率和避免有毒氰基源。同时，该协议可以成功地应用于放大合成。3-氰基喹啉的进一步化学转化可以产生一些有价值的骨架，证明其在合成应用中的潜力
• 一种3-腈基喹啉衍生物及其制备方法
  申请人：郑州大学

  公开号：CN113620875B

  公开（公告）日：2023-06-23

  本发明公开了一种3‑腈基喹啉衍生物，结构式如式Ⅰ所示：其中R1为氢、烷基或芳基；R2～R5各自独立的为氢、卤素、烷基、烷氧基、三氟甲基、酯基、羟基或氨基；R6为氢、烷基、酯基、芳基或取代的芳基。本发明提供的3‑腈基喹啉衍生物，R1～R6位可连接多种取代基，是一种用途广泛的有机合成中间体，在医药及有机合成领域具有重要的应用价值。本发明还提供了一种3‑腈基喹啉衍生物的制备方法，该制备方法可在空气条件下进行，反应条件温和，易于控制，所用原料易得，不需要有毒的腈化物作为腈基来源，底物适用范围广，反应转化率高，在较短时间内可以得到较高的选择性和收率，且后处理简便、绿色环保，适合大规模工业化生产。
• Substituted 3-cyano quinolines
  申请人：American Cyanamid Company

  公开号：US06002008A1

  公开（公告）日：1999-12-14

  This invention provides compounds having the formula: ##STR1## wherein: X is cycloalkyl which may be optionally substituted; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally substituted; n is 0-1; Y is --NH--, --O--, --S--, or --NR--; R is alkyl of 1-6 carbon atoms; R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are each, independently, hydrogen, halogen, alkyl, alkenyl, alkynyl, alkenyloxy, alkynyloxy, hydroxymethyl, halomethyl, alkanoyloxy, alkenoyloxy, alkynoyloxy, alkanoyloxymethyl, alkenoyloxymethyl, alkynoyloxymethyl, alkoxymethyl, alkoxy, alkylthio, alkylsulphinyl, alkylsulphonyl, alkylsulfonamido, alkenylsulfonamido, alkynylsulfonamido, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy, carboalkyl, phenoxy, phenyl, thiophenoxy, benzyl, amino, hydroxyamino, alkoxyamino, alkylamino, dialkylamino, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, phenylamino, benzylamino, ##STR2## R.sub.5 is alkyl which may be optionally substituted, or phenyl which may be optionally substituted; R.sub.6 is hydrogen, alkyl, or alkenyl; R.sub.7 is chloro or bromo R.sub.8 is hydrogen, alkyl, aminoalkyl, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-cycloalkylaminoalkyl, N-cycloalkyl-N-alkylaminoalkyl, N,N-dicycloalkylaminoalkyl, morpholino-N-alkyl, piperidino-N-alkyl, N-alkyl-piperidino-N-alkyl, azacycloalkyl-N-alkyl, hydroxyalkyl, alkoxyalkyl, carboxy, carboalkoxy, phenyl, carboalkyl+, chloro, fluoro, or bromo; Z is amino, hydroxy, alkoxy, alkylamino, dialkylamino, morpholino, piperazino, N-alkylpiperazino, or pyrrolidino; m=1-4,q=1-3, and p=0-3; any of the substituents R.sub.1, R.sub.2, R.sub.3, or R.sub.4 that are located on contiguous carbon atoms can together be the divalent radical --O--C(R.sub.8).sub.2 --O--; or a pharmaceutically acceptable salt thereof with the proviso that when Y is --NH--, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are hydrogen, and n is 0, X is not 2-methylphenyl, which are inhibitors of protein tyrosine kinase.

  该发明提供了具有以下结构的化合物：##STR1## 其中：X是环烷基，可以选择性地被取代；或是吡啶基，嘧啶基或苯基；其中吡啶基，嘧啶基或苯基可以选择性地被取代；n为0-1；Y为--NH--，--O--，--S--或--NR--；R为1-6个碳原子的烷基；R.sub.1、R.sub.2、R.sub.3和R.sub.4各自独立地为氢、卤素、烷基、烯基、炔基、烯氧基、炔氧基、羟甲基、卤代甲基、脂肪酸酯氧基、烯酸酯氧基、炔酸酯氧基、脂肪酸酯氧甲基、烯酸酯氧甲基、炔酸酯氧甲基、甲氧基甲基、甲氧基、烷硫基、烷基亚磺酰基、烷基磺酰基、烷基磺酰胺基、烯基磺酰胺基、炔基磺酰胺基、羟基、三氟甲基、氰基、硝基、羧基、羧基烷氧基、羧基烷基、苯氧基、苯基、噻吩氧基、苄基、氨基、羟胺基、烷氧胺基、烷基胺基、二烷基胺基、氨基烷基、N-烷基氨基烷基、N，N-二烷基氨基烷基、苯基氨基、苄氨基、##STR2## R.sub.5是可以选择性取代的烷基或苯基；R.sub.6是氢、烷基或烯基；R.sub.7是氯或溴；R.sub.8是氢、烷基、氨基烷基、N-烷基氨基烷基、N，N-二烷基氨基烷基、N-环烷基氨基烷基、N-环烷基-N-烷基氨基烷基、N，N-二环烷基氨基烷基、吗啉-N-烷基、哌啶-N-烷基、N-烷基-哌啶-N-烷基、杂环烷基-N-烷基、羟基烷基、烷氧基烷基、羧基、羧基烷氧基、苯基、羧基烷基+、氯、氟或溴；Z是氨基、羟基、烷氧基、烷基胺基、二烷基胺基、吗啉、哌嗪、N-烷基哌嗪或吡咯烷基；m=1-4，q=1-3，p=0-3；任何位于相邻碳原子上的R.sub.1，R.sub.2，R.sub.3或R.sub.4的取代基可以共同成为二价基团--O--C(R.sub.8).sub.2--O--；或其药学上可接受的盐，但当Y为--NH--，R.sub.1，R.sub.2，R.sub.3和R.sub.4为氢，n为0时，X不是2-甲基苯基，这些化合物是蛋白酪氨酸激酶抑制剂。